Renalytix first half revenues rise, but cautions pipeline is taking longer to convert

Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) grew first-half revenue to US$1.6 million and trimmed its underlying EBITDA loss, but said full-year sales are now expected to come in at around US$4 million as healthcare-system integrations take longer to convert into revenue. The kidney disease diagnostics group said revenue for the six months to 31 December 2025 rose from US$1.3 million a year earlier, while underlying EBITDA loss narrowed to US$6.4 million from US$7.2 million and operating loss improved to US$7.1 million from US$7.5 million.